Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SOLAGE is a topical solution approved in 1999 by Almirall for an undisclosed indication. The exact mechanism of action and pharmacologic class are not publicly available in this dataset, limiting clinical context for career professionals.
Product is in late-stage lifecycle with approaching loss of exclusivity; team focus likely shifting to lifecycle management and transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases
Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
Worked on SOLAGE at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and approaching LOE, SOLAGE represents a sunset career opportunity rather than a growth platform. Professionals assigned to this product should expect focus on margin optimization, generic transition management, and organizational realignment rather than field expansion or new indication launches.